Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer

Revathi Kollipara, Bryan Schneider, Milan Radovich, Sunil Babu, Patrick J. Kiel

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. This led to substantial regression of tumor nodules. Genomic sequencing-based approaches to identify therapeutic targets has potential for improving outcomes. Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab

Original languageEnglish (US)
Pages (from-to)1149-1151
Number of pages3
JournalOncologist
Volume22
Issue number10
DOIs
StatePublished - Oct 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer'. Together they form a unique fingerprint.

  • Cite this